All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076459" target="_blank" >RIV/65269705:_____/22:00076459 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/22:00126321

  • Result on the web

    <a href="https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.tem.2022.06.005" target="_blank" >10.1016/j.tem.2022.06.005</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

  • Original language description

    Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30202 - Endocrinology and metabolism (including diabetes, hormones)

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Trends in Endocrinology and Metabolism

  • ISSN

    1043-2760

  • e-ISSN

    1879-3061

  • Volume of the periodical

    33

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    11

  • Pages from-to

    628-638

  • UT code for WoS article

    000877913500003

  • EID of the result in the Scopus database

    2-s2.0-85134850918